{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"27.360","floor":"26.360"},"ipodate":{"start":"2021-01-27 00:00:00","end":"2021-02-01 00:00:00"},"minimumcapital":"13817.85","subscribed":"402.80","marketcap":"72.96億","H_marketcap":"20.27億","pe":"--","codesrate":"10.00","link":"https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0127/2021012700022_c.pdf","ipopricing":"27.360","resultdate":"2021-02-05 00:00:00","enddate":"2021-02-01 00:00:00","listeddate":"2021-02-08 00:00:00","issuenumber":"6666.70萬","issuenumberhK":"3333.50萬","issuenumberother":"3333.20萬","grayprice":"31.20","sponsors":"中信里昂證券資本市場有限公司","raisemoney":"171670.00萬","use":"1、約30%或515.0百萬港元將分配予我們的核心產品PGT-A試劑盒；\n2、約20%或343.3百萬港元將用于PGT-M試劑盒的臨床試驗、注冊申報及商業化；\n3、約30%或515.0百萬港元將分配用于我們其他產品的開發、臨床試驗及注冊申報；\n4、約10%或171.7百萬港元將用于提高我們的研發能力及提升我們的技術；\n5、約10%或171.7百萬港元將用作我們的營運資本及一般企業用途。","shares":500,"leadagent":"中信里昂證券有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司,海通國際證券有限公司,招銀國際融資有限公司,工銀國際證券有限公司,浦銀國際融資有限公司,富途證券國際(香港)有限公司","bookrunners":"中信里昂證券有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司,海通國際證券有限公司,招銀國際融資有限公司,工銀國際融資有限公司,浦銀國際融資有限公司","coordinator":"中信里昂證券有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司","firstDayOpen":"30.00","IsEiio":0,"Interestdays":4,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"中信里昂證券有限公司","code":"E02170","name":"貝康醫療－Ｂ","fullname":"蘇州貝康醫療股份有限公司"},"institutioninfo":{"principaloffice":"中國江蘇省蘇州市蘇州工業園區星湖街218號生物納米園A3樓101室","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"梁波","secretary":"戴靜,嚴洛鈞","telephone":"400 188 7878","substantialshareholders":"梁波(20.71%),貝康投資(13.53%),中誠方圓二期(5.70%),高瓴香港(5.11%)","principalactivities":"公司是中國輔助生殖基因檢測解決方案最領先創新平臺。","website":"http://www.basecare.cn"},"managerinfo":[{"managername":"梁波","post":"董事長、總經理兼執行董事","rankno":1},{"managername":"孔令印","post":"執行董事","rankno":2},{"managername":"芮茂社","post":"執行董事","rankno":3}],"investorinfo":[{"institutionname":"Lake Bleu Prime Healthcare Master Fund Limited","shareholding":"5,667,500.0","percentage":8.5,"ReleaseDate":"2021-08-08 00:00:00","relatedparty":"清池資本(香港)有限公司","subsidiary":["Lake Bleu Prime Healthcare Master Fund Limited"],"InverstorType":"基金"},{"institutionname":"OrbiMed Funds","shareholding":"5,667,500.0","percentage":8.5,"ReleaseDate":"2021-08-08 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"CRF Investment Holdings Company Limited","shareholding":"5,667,500.0","percentage":8.5,"ReleaseDate":"2021-08-08 00:00:00","relatedparty":"China Reform Conson Soochow Overseas Fund I L.P.","subsidiary":["CRF Investment Holdings Company Limited"],"InverstorType":"公司"},{"institutionname":"Affin Hwang Asset Management Berhad","shareholding":"2,833,500.0","percentage":4.3,"ReleaseDate":"2021-08-08 00:00:00","relatedparty":"Affin Hwang Investment Bank Berhad","subsidiary":["Affin Hwang Asset Management Berhad"],"InverstorType":"公司"}],"TotalShareholdingPercentage":38.3},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}